Systematic Design of Trypsin Cleavage Site Mutated Exendin4-Cysteine 1, an Orally Bioavailable Glucagon-Like Peptide-1 Receptor Agonist

Computational polypharmacology: a new paradigm for drug discovery

(2017) Rajan Chaudhari et al.   Expert Opinion on Drug Discovery

Oral absorption of peptides and nanoparticles across the human intestine: Opportunities, limitations and studies in human tissues

(2016) P. Lundquist et al.   ADVANCED DRUG DELIVERY REVIEWS

Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation

(2016) Maria Yu et al.   CLINICAL THERAPEUTICS

Perceptions and experiences of taking oral medications for the treatment of Type 2 diabetes mellitus: a systematic review and meta-synthesis of qualitative studies

(2016) J. McSharry et al.   DIABETIC MEDICINE

Absorption-enhancing effects of gemini surfactant on the intestinal absorption of poorly absorbed hydrophilic drugs including peptide and protein drugs in rats

(2016) Tammam Alama et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Truncated Glucagon-like Peptide-1 and Exendin-4 α-Conotoxin pl14a Peptide Chimeras Maintain Potency and α-Helicity and Reveal Interactions Vital for cAMP Signalingin Vitro

(2016) Joakim E. Swedberg et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Albiglutide: A once-weekly glucagon-like peptide-1 receptor agonist for type 2 diabetes mellitus

(2015) P. N. Davis et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Lessons learned from the clinical development of oral peptides

(2015) Morten Asser Karsdal et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

(2015) Jesper Lau et al.   JOURNAL OF MEDICINAL CHEMISTRY

The Short-Term Cost-Effectiveness of Once-Daily Liraglutide Versus Once-Weekly Exenatide for the Treatment of Type 2 Diabetes Mellitus in the United States

(2015) Bruce Wang et al.   PLoS One

Albiglutide

(2014) Jennifer M. Trujillo et al.   ANNALS OF PHARMACOTHERAPY

Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial

(2014) Benjamin M. Scirica et al.   CIRCULATION

The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes

(2013) Gregory Gaich et al.   Cell Metabolism

Approaches for enhancing oral bioavailability of peptides and proteins

(2013) Jwala Renukuntla et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

A free cysteine prolongs the half-life of a homing peptide and improves its tumor-penetrating activity

(2013) Hong-Bo Pang et al.   JOURNAL OF CONTROLLED RELEASE

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

(2012) Kerry Hunter et al.   BMC NEUROSCIENCE

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

(2012) Juris J. Meier   Nature Reviews Endocrinology

Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study

(2011) S. Irie et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Glucagon-like Peptide-1 Increases β-Cell Glucose Competence and Proliferation by Translational Induction of Insulin-like Growth Factor-1 Receptor Expression

(2010) Marion Cornu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

GLP-1 Mediates Antiapoptotic Effect by Phosphorylating Bad through a β-Arrestin 1-mediated ERK1/2 Activation in Pancreatic β-Cells

(2009) Julie Quoyer et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

(2009) John B Buse et al.   LANCET

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents

(2009) Jonathan W Day et al.   Nature Chemical Biology

Passing the baton in class B GPCRs: peptide hormone activation via helix induction?

(2009) Christoph Parthier et al.   TRENDS IN BIOCHEMICAL SCIENCES